Lymph node (LN) metastases after primary treatment may end up with disease recurrence and poor survival rate. Here this group designs a phospholipase A2 (sPLA2)-responsive nanosystem delivering doxorubicin for in vivo inhibition of both primary colorectal tumor progression and LN metastasis.
- Yihang Yuan
- Quanjun Lin
- Chao Fang